collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
240 papers 100 to 500 followers
https://www.readbyqxmd.com/read/28528449/the-canadian-national-breast-screening-studies-are-compromised-and-their-results-are-unreliable-they-should-not-factor-into-decisions-about-breast-cancer-screening
#1
REVIEW
Daniel B Kopans
The Canadian National Breast Screening Studies were compromised by an unblinded allocation process and poor quality mammography. Contrary to the requirement that allocation in a randomized controlled trial (RCT) be blinded to avoid any possible intentional or unintentional subversion of a random allocation, all women in the CNBSS trials underwent a clinical breast examination prior to assignment to the study arm or the usual care arm. Women with abnormal clinical breast examinations were identified, and this information was available to the coordinators who then assigned the women on open lists...
May 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28532503/an-updated-predict-breast-cancer-prognostication-and-treatment-benefit-prediction-model-with-independent-validation
#2
Francisco J Candido Dos Reis, Gordon C Wishart, Ed M Dicks, David Greenberg, Jem Rashbass, Marjanka K Schmidt, Alexandra J van den Broek, Ian O Ellis, Andrew Green, Emad Rakha, Tom Maishman, Diana M Eccles, Paul D P Pharoah
BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific mortality in women diagnosed under the age of 40. Another limitation is the use of discrete categories for tumour size and node status resulting in 'step' changes in risk estimates on moving between categories. We have refitted the PREDICT prognostic model using the original cohort of cases from East Anglia with updated survival time in order to take into account age at diagnosis and to smooth out the survival function for tumour size and node status...
May 22, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28508184/nationwide-cross-sectional-adherence-to-mammography-screening-guidelines-national-behavioral-risk-factor-surveillance-system-survey-results
#3
Anand Narayan, Alexander Fischer, Zihe Zhang, Ryan Woods, Elizabeth Morris, Susan Harvey
PURPOSE: Varying recommendations about breast cancer screening have generated much confusion about when and how often to undergo mammography screening, yet there is limited population-based data about the extent to which patients adhere to various mammographic screening guidelines in practice. Our purpose was to evaluate population-based adherence to mammographic screening using criteria from major guideline-producing organizations. METHODS: Women aged 40-74 in the 2014 Behavioral Risk Factor Surveillance System survey were included...
May 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28521178/impact-of-2013-asco-cap-guidelines-on-her2-determination-of-invasive-breast-cancer-a-single-institution-experience-using-frontline-dual-color-fish
#4
M Ragazzi, A Bisagni, E Gasparini, E Kuhn, C Bassano, I Tamagnini, M Foroni, M Bortesi, G Falco, G Ferrari, L Braglia, L Savoldi, A Bologna, R Di Cicilia, G Bisagni, G Gardini
PURPOSE: The new ASCO/CAP guidelines published in 2013 (AC2013) significantly modified the scoring criteria for HER2-FISH, introducing the most controversial change to the HER2-equivocal category. We retrospectively evaluated the impact of AC2013 in a cohort of consecutive invasive breast cancers (IBCs) analyzed with frontline dual-color FISH. METHODS: 2788 consecutive IBCs were reclassified based on the AC2013 guidelines. Clinico-pathological features of equivocal IBCs were compared with HER2-negative and HER2-positive IBCs...
May 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28503075/imprint-cytology-versus-frozen-section-analysis-for-intraoperative-assessment-of-sentinel-lymph-node-in-breast-cancer
#5
Thalia Petropoulou, Antonia Kapoula, Aikaterini Mastoraki, Aikaterini Politi, Eleni Spanidou-Karvouni, Ioannis Psychogios, Ioannis Vassiliou, Nikolaos Arkadopoulos
INTRODUCTION: Sentinel lymph node (SLN) biopsy is the gold standard for surgical staging of the axilla in breast cancer (BC). Frozen section (FS) remains the most popular means of intraoperative SLN diagnosis. Imprint cytology (IC) has also been suggested as a less expensive and equally accurate alternative to FS. The aim of our study was to perform a direct comparison between IC and FS on the same SLNs of BC cases operated in a single center by the same surgical team. MATERIALS AND METHODS: Into this prospective study we enrolled 60 consecutive patients with histologically proven T1-T3 BC and clinically negative axilla...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28485826/triple-negative-breast-cancer-in-the-elderly-prognosis-and-treatment
#6
Henry G Kaplan, Judith A Malmgren, Mary K Atwood
Our objective is to characterize treatment of triple-negative breast cancer (TNBC) in older patients and measure mortality risk relative to younger women. We conducted a retrospective cohort study analysis of patients presenting with primary TNBC, age 25-93, stage I-III from 1990 to 2014, identified and tracked by our registry (n=771). Clinical characteristics were chart abstracted at diagnosis and follow-up. The Kaplan-Meier method was used to measure disease-specific survival (DSS) by age with Cox regression modeling for relative contribution of patient and clinical characteristics...
May 9, 2017: Breast Journal
https://www.readbyqxmd.com/read/28484921/preoperative-prediction-of-node-negative-disease-after-neoadjuvant-chemotherapy-in-patients-presenting-with-node-negative-or-node-positive-breast-cancer
#7
Brittany L Murphy, Tanya L Hoskin, Courtney Day N Heins, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: Axillary node status after neoadjuvant chemotherapy (NAC) influences the axillary surgical staging procedure as well as recommendations regarding reconstruction and radiation. OBJECTIVE: Our aim was to construct a clinical preoperative prediction model to identify the likelihood of patients being node negative after NAC. METHODS: Using the National Cancer Database (NCDB) from January 2010 to December 2012, we identified cT1-T4c, N0-N3 breast cancer patients treated with NAC...
May 8, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28493552/multigene-assays-implications-for-breast-cancer-staging
#8
EDITORIAL
Frederick L Greene
No abstract text is available yet for this article.
May 11, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28433541/the-impact-of-2013-updated-asco-cap-her2-guidelines-on-the-diagnosis-and-management-of-invasive-breast-cancer-a-single-center-study-of-1739-cases
#9
Xiaofei Zhang, Ira Bleiweiss, Shabnam Jaffer, Anupma Nayak
BACKGROUND: The purpose of this study was to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists. MATERIALS AND METHODS: Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014). RESULTS: Using 2013 guidelines, 255 (15%; 95% confidence interval [CI], 13%-16%) cases were classified as HER2(+) as opposed to 186 (11%; 95% CI, 9%-12%) by 2007 guidelines (odds ratio [OR] 1...
March 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28436999/clinical-practice-guidelines-on-the-evidence-based-use-of-integrative-therapies-during-and-after-breast-cancer-treatment
#10
REVIEW
Heather Greenlee, Melissa J DuPont-Reyes, Lynda G Balneaves, Linda E Carlson, Misha R Cohen, Gary Deng, Jillian A Johnson, Matthew Mumber, Dugald Seely, Suzanna M Zick, Lindsay M Boyce, Debu Tripathy
Answer questions and earn CME/CNE Patients with breast cancer commonly use complementary and integrative therapies as supportive care during cancer treatment and to manage treatment-related side effects. However, evidence supporting the use of such therapies in the oncology setting is limited. This report provides updated clinical practice guidelines from the Society for Integrative Oncology on the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy-induced nausea and vomiting, lymphedema, chemotherapy-induced peripheral neuropathy, pain, and sleep disturbance...
April 24, 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28455673/population-based-analysis-of-breast-cancer-incidence-and-survival-outcomes-in-women-diagnosed-with-lobular-carcinoma-in-situ
#11
Stephanie M Wong, Tari King, Jean-Francois Boileau, William T Barry, Mehra Golshan
PURPOSE: A diagnosis of lobular carcinoma in situ (LCIS) is associated with an increased risk of developing breast cancer, although little data exist on long-term patient outcomes, including those who develop subsequent breast malignancies. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women with a histological diagnosis of LCIS between 1983 and 2014. The incidence and clinicopathologic features of subsequent malignancies were then examined, and the Kaplan-Meier method and multivariable Cox PH regression used to obtain breast cancer-specific survival (BCSS) estimates and associated hazard ratios...
April 28, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28453704/genomic-characterization-of-her2-positive-breast-cancer-and-response-to-neoadjuvant-trastuzumab-and-chemotherapy-results-from-the-acosog-z1041-alliance-trial
#12
R Lesurf, O L Griffith, M Griffith, J Hundal, L Trani, M A Watson, R Aft, M J Ellis, D Ota, V J Suman, F Meric-Bernstam, A M Leitch, J C Boughey, G Unzeitig, A U Buzdar, K K Hunt, E R Mardis
Background: HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15-30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College of Surgeons Oncology Group Z1041 trial (NCT00513292) was designed to compare the pathologic complete response (pCR) rate of distinct regimens of neoadjuvant chemotherapy and trastuzumab, but ultimately identified no difference. Patients and methods: In supplement to tissues from 37 Z1041 cases, 11 similarly treated cases were obtained from a single institution study (NCT00353483)...
May 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28444533/breast-cancer-risk-models-a-comprehensive-overview-of-existing-models-validation-and-clinical-applications
#13
REVIEW
Jessica A Cintolo-Gonzalez, Danielle Braun, Amanda L Blackford, Emanuele Mazzola, Ahmet Acar, Jennifer K Plichta, Molly Griffin, Kevin S Hughes
Numerous models have been developed to quantify the combined effect of various risk factors to predict either risk of developing breast cancer, risk of carrying a high-risk germline genetic mutation, specifically in the BRCA1 and BRCA2 genes, or the risk of both. These breast cancer risk models can be separated into those that utilize mainly hormonal and environmental factors and those that focus more on hereditary risk. Given the wide range of models from which to choose, understanding what each model predicts, the populations for which each is best suited to provide risk estimations, the current validation and comparative studies that have been performed for each model, and how to apply them practically is important for clinicians and researchers seeking to utilize risk models in their practice...
April 25, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28448864/new-agents-for-endocrine-resistance-in-breast-cancer
#14
REVIEW
Christian Maurer, Samuel Martel, Dimitrios Zardavas, Michail Ignatiadis
Estrogen receptor positive (ER+) and HER2-negative (HER2-) breast cancer (BC) is the most common BC subtype, defined by expression of the ER and absence of HER2 amplification. Endocrine treatment (ET), aiming at therapeutic blockade of ER signaling, represents the therapeutic mainstay for patients with both early and advanced disease. Despite its wide therapeutic efficacy, ET fails for a proportion of ER+, HER2- BC patients with early disease who develop endocrine resistance, resulting in disease recurrence...
April 24, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28423155/the-role-of-genetic-testing-in-patients-with-breast-cancer-a-review
#15
Olivia M Valencia, Selyne E Samuel, Rebecca K Viscusi, Taylor S Riall, Leigh A Neumayer, Hassan Aziz
Importance: In the United States from 2009 to 2013, the incidence of breast cancer was the highest of any cancer and the death rate was second to that of lung cancer. Approximately 5% to 10% of breast cancers are inheritable. Observations: BRCA1 and BRCA2 germline mutations account for up to 30% of inheritable breast cancers and are the most commonly assessed mutations in patients presenting with early-onset breast cancer, triple-negative breast cancer, bilateral breast cancer, and a family history of breast cancer...
April 19, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28423171/identification-of-patients-with-documented-pathologic-complete-response-in-the-breast-after-neoadjuvant-chemotherapy-for-omission-of-axillary-surgery
#16
Audree B Tadros, Wei T Yang, Savitri Krishnamurthy, Gaiane M Rauch, Benjamin D Smith, Vicente Valero, Dalliah M Black, Anthony Lucci, Abigail S Caudle, Sarah M DeSnyder, Mediget Teshome, Carlos H Barcenas, Makesha Miggins, Beatriz E Adrada, Tanya Moseley, Rosa F Hwang, Kelly K Hunt, Henry M Kuerer
Importance: A pathologic complete response (pCR; no invasive or in situ cancer) occurs in 40% to 50% of patients with HER2-positive (HER2+) and triple-negative (TN) breast cancer. The need for surgery if percutaneous biopsy of the breast after neoadjuvant chemotherapy (NCT) indicates pCR in the breast (hereinafter referred to as breast pCR) has been questioned, and appropriate management of the axilla in such patients is unknown. Objective: To identify patients among exceptional responders to NCT with a low risk for axillary metastases when breast pCR is documented who may be eligible for an omission of surgery clinical trial design...
April 19, 2017: JAMA Surgery
https://www.readbyqxmd.com/read/28427528/mechanisms-of-chemotherapy-induced-ovarian-damage-in-breast-cancer-patients
#17
REVIEW
Giovanni Codacci-Pisanelli, Lino Del Pup, Maria Del Grande, Fedro A Peccatori
Fertility preservation in breast cancer patients is an increasingly relevant topic. In the present paper we review available data on the mechanism of ovarian damage caused by anticancer agents currently used for the treatment of breast cancer. We also describe current methods to preserve fertility including oocytes or ovarian tissue freezing and administration of LH-RHa during chemotherapy. The aim of the paper is to provide clinical oncologists with an adequate knowledge of the subject to enable them to give a correct counselling to young women that must receive chemotherapy and want to increase their possibilities of maintaining fertility...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28417238/bilateral-mastectomy-as-overtreatment-for-breast-cancer-in-women-age-forty-years-and-younger-with-unilateral-operable-invasive-breast-cancer
#18
Cory A Donovan, Jean Bao, Alexandra Gangi, Farin Amersi, Xiao Zhang, Armando E Giuliano, Alice P Chung
BACKGROUND: Young women with breast cancer (BC) have an increased risk of contralateral breast cancer (CBC) compared with older women. This may contribute to the rising rates of bilateral mastectomy (BM), but it is unclear if BM leads to improved outcomes. METHODS: A prospectively maintained database was reviewed. Patient and tumor characteristics, survival, and rate of CBC were compared in women age ≤40 years treated for unilateral Stage 1-3 BC from January 2000 through December 2013...
April 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28404755/nccn-guidelines-insights-breast-cancer-version-1-2017
#19
William J Gradishar, Benjamin O Anderson, Ron Balassanian, Sarah L Blair, Harold J Burstein, Amy Cyr, Anthony D Elias, William B Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P Goetz, Lori J Goldstein, Steven J Isakoff, Janice Lyons, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Meena S Moran, Ruth M O'Regan, Sameer A Patel, Lori J Pierce, Elizabeth C Reed, Kilian E Salerno, Lee S Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H Ward, Dorothy A Shead, Rashmi Kumar
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.
April 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28414115/cost-analysis-of-a-surgical-consensus-guideline-in-breast-conserving-surgery
#20
Jennifer Yu, Leisha C Elmore, Amy E Cyr, Rebecca L Aft, William E Gillanders, Julie A Margenthaler
BACKGROUND: The Society of Surgical Oncology and American Society of Radiation Oncology consensus statement was the first professional guideline in breast oncology to declare "no ink on tumor" as a negative margin in patients with stages I/II breast cancer undergoing breast-conservation therapy. We sought to analyze the financial impact of this guideline at our institution using a historic cohort. STUDY DESIGN: We identified women undergoing re-excision after breast-conserving surgery for invasive breast cancer from 2010 through 2013 using a prospectively maintained institutional database...
April 14, 2017: Journal of the American College of Surgeons
label_collection
label_collection
6331
1
2
2017-04-19 22:36:41
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"